Target intelligence / Profile preview

UFM1-specific ligase 1 (UFL1)

Target
UFL1
Molecular classification
Enzyme (E3 ligase), Ubiquitin-like modifier ligase (UFMylation E3 ligase), Scaffold-type E3 ligase
01

Overview

UFM1-specific ligase 1 (UFL1) is the sole known E3 ligase responsible for catalyzing UFM1 (ubiquitin-fold modifier 1) conjugation (ufmylation) to protein substrates in eukaryotic cells, a process essential for regulating endoplasmic reticulum (ER) homeostasis, stress responses, hematopoiesis, and multiple other biological processes[1][2][3]. UFL1 forms a complex with adaptor proteins such as DDRGK1 and CDK5RAP3 to exert its E3 ligase activity, acting as a scaffold-type ligase, and is usually anchored on the cytoplasmic ER membrane[1][2][3]. UFL1 deficiency leads to complete loss of ufmylation, hematopoietic failure, and embryonic lethality in animal models, highlighting its essential role in cell survival and organ development, and connecting UFL1 to diseases such as cancer, inflammatory conditions, and ER-stress pathologies[1][3]. No drugs currently target UFL1 directly, but its unique and central role in the UFMylation pathway makes it a potential therapeutic target under investigation[1][3].

Other names
E3 UFM1-protein ligase 1KIAA0776MAXERRCADNLBPE3 UFM1-protein transferase 1Multiple alpha-helix protein located at ERNovel LZAP-binding proteinRegulator of C53/LZAP and DDRGK1Regulator of CDK5RAP3 and DDRGK1LZAP-binding protein
02

Mechanism of action

Scaffold for E2 (UFC1) and substrate recruitment to catalyze UFM1 transfer (protein ufmylation)

03

Biological functions

Protein ufmylation (UFM1 conjugation)Endoplasmic reticulum (ER) homeostasis and stress responseHematopoiesisDNA damage responseAutophagyLiver and kidney developmentRegulation of cell homeostasisRegulation of protein translation
04

Disease associations

CancerInflammationER-stress related disordersHematopoietic failure
05

Safety considerations

Loss of UFL1 function results in severe developmental defects such as hematopoietic failure and embryonic lethality in knockout models, indicating essential cellular roles[3].ER stress modulation could present therapeutic challenges and off-target effects in cases of inhibition[1][3].No drugs currently known to target UFL1 directly; safety profile is theoretical based on knockout and functional studies[1][3].

Beyond the preview

Go deeper on UFM1-specific ligase 1 (UFL1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on UFM1-specific ligase 1 (UFL1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call